TRCT
XBIO icon

Tower Research Capital (TRC)’s Xenetic Biosciences XBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02K Sell
696
-110
-14% -$340 ﹤0.01% 4732
2026
Q1 		$2.16K Sell
806
-3,206
-80% -$7.91K ﹤0.01% 4532
2025
Q4 		$8.71K Buy
+4,012
New +$12.8K ﹤0.01% 3936
2024
Q4 		– Sell
-692
Closed -$2.99K – 6049
2024
Q3 		$2.99K Buy
+692
New +$2.72K ﹤0.01% 4912
2024
Q2 		– Sell
-925
Closed -$3.49K – 6046
2024
Q1 		$3.49K Sell
925
-95
-9% -$363 ﹤0.01% 4855
2023
Q4 		$3.52K Sell
1,020
-364
-26% -$1.28K ﹤0.01% 5070
2023
Q3 		$6.78K Buy
1,384
+763
+123% +$3.19K ﹤0.01% 4557
2023
Q2 		$2.04K Sell
621
-514
-45% -$1.91K ﹤0.01% 5264
2023
Q1 		$5K Hold
1,135
– – ﹤0.01% 5002
2022
Q4 		$3K Sell
1,135
-34
-3% -$150 ﹤0.01% 5249
2022
Q3 		$6K Sell
1,169
-269
-19% -$2.13K ﹤0.01% 5072
2022
Q2 		$12K Buy
1,438
+1,258
+699% +$10.2K ﹤0.01% 4322
2022
Q1 		$2K Buy
180
+178
+8,900% +$1.86K ﹤0.01% 5616
2021
Q4 		$0 Sell
2
-299
-99% -$4.77K ﹤0.01% 6623
2021
Q3 		$6K Buy
+301
New +$8.2K ﹤0.01% 4781
2017
Q2 		– Sell
-8
Closed -$5K – 3532
2017
Q1 		$5K Buy
+8
New +$4.25K ﹤0.01% 2236

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Tower Research Capital (TRC)'s XBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Xenetic Biosciences (XBIO) stake by 14% in Q2 2026, selling an estimated $340 and leaving 696 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Tower Research Capital (TRC) first reported a position in XBIO in Q1 2017 and has held it in 16 quarters since. The position peaked at $12K in Q2 2022. 8 funds tracked by Wall St. Rank hold XBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 696 shares of Xenetic Biosciences worth $2.02K as of Q2 2026.
  • Tower Research Capital (TRC) sold 110 Xenetic Biosciences shares in Q2 2026, an estimated $340.
  • Xenetic Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4732 holding.
  • Tower Research Capital (TRC) first reported a position in Xenetic Biosciences in Q1 2017 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Xenetic Biosciences position peaked at $12K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.